Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

24.08 +1.01 (+4.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Myriad Genetics Inc

< Previous 1 2 3 4 Next >
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Management will also participate in two upcoming healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
The Myriad Collaborative Research Registry has more than one million patient cases 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx... 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Stephens Annual Investment Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
Myriad to also host Investor Day in South San Francisco in September 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancer 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Host Investor Day on September 19, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.